Clinical Trial Update: Post-Operative Use of FS2 to Mitigate Scarring in Burn Patients [Phase 2, Phase 3]

View source ↗

Summary

FS2 is being evaluated in Phase 2/Phase 3 trials to reduce scarring after burn surgery; recruitment is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Burn Scar
• Burn Wound
• Burns

Drugs mentioned

• FS2

Snippet

Sponsor: Birch BioMed Inc | Conditions: Burn Scar, Burn Wound | Phase 2, Phase 3 | Status: RECRUITING